DBVT · DBV Technologies S.A.

Summary

DBV Technologies S.A. reported full year 2025 financial results including operating income of $5.6 million, net loss of $147.0 million, and cash and cash equivalents of $194.2 million as of December 31, 2025, plus $94 million additional proceeds received January 16, 2026, funding into Q2 2027. The company advanced VIASKIN Peanut Patch clinical programs, bolstered leadership, and anticipates BLA submissions in 2026.

Key takeaways

• Event Type: Full Year 2025 Financial Results and Business Update (Items: 2.02)